Journals / Ankara Eğitim ve Araştırma Hastanesi Tıp Dergisi / 2020 / Cilt: 53 - Sayı: Ek sayı

EVALUATION OF DEMOGRAPHIC, CLINICAL AND LABORATORY CHARACTERISTICS OF PATIENTS FOLLOWED WITH HERPES ZOSTER

HERPES ZOSTER TANISIYLA TAKİP EDİLEN HASTALARIN DEMOGRAFİK, KLİNİK VE LABORATUVAR ÖZELLİKLERİNİN DEĞERLENDİRİLMESİ

Pages
33–40
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

CONCLUSION: Identification of risk factor for ocular involvement and HZ epidemiology may help the physician during patient management.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:AIM: Herpes zoster (HZ) is caused by reactivation of varicella zoster virus and it is more prominent among elderly and patients with immune suppression.
📊
Key Findings & Data:Although a decrease in both incidence and complication of HZ is observed after the zoster vaccine became available, HZ remains a problem in developing counties.
💡
Conclusion & Impact:CONCLUSION: Identification of risk factor for ocular involvement and HZ epidemiology may help the physician during patient management.
🔬Design:Review & Systematic Survey
📍Scope:2014 Verileri
⚙️Variables:Domain Parameters

Abstract

AIM: Herpes zoster (HZ) is caused by reactivation of varicella zoster virus and it is more prominent among elderly and patients with immune suppression. Although a decrease in both incidence and complication of HZ is observed after the zoster vaccine became available, HZ remains a problem in developing counties. The aim of this study is to evaluate demographic, clinical and laboratory characteristics of patients with HZ. MATERIAL AND METHOD: Patients administered to dermatology clinic with HZ between May 2014-May 2018 were identified by ICD 10 codes (B02, B02.3, B02.8, B02.9). Electronic chards of 3856 patients were reviewed and disease features were recorded. RESULTS: Forty-seven point six of the patients were male and 52.4% were female. The main age was calculated as 50.89 (±18.3). Incidence of HZ did not vary with season (spring: 27.1%, summer: 22.9%, autumn: 25.6%, winter: 24.4%) but hospitalization and ocular complication rates tended to increase in spring (spring: 36%, summer: 23%, autumn: 25%, winter: 16%) and autumn (spring: 23.1%, summer: 7.7%, autumn: 53.8%, winter: 15.4%) seasons respectively. Ocular involvement was observed in 13% of the hospitalized patients. Patients administered in autumn had a higher risk of ocular involvement compared to other seasons (OR: 4.87, 95% CI: 1.28-18.53, p=0.020). Every one-unit decrease in PDW and every one-year increase in age increased the risk of ocular complications by 1.29 (95% CI: 1.01-1.69, p=0.048) and 1.08 (95% CI: 1.009-1.156, p=0.026) fold respectively. CONCLUSION: Identification of risk factor for ocular involvement and HZ epidemiology may help the physician during patient management.

Özet

AMAÇ: Herpes zoster (HZ), varisella zoster virüsünün reaktivasyonusonucu meydana gelir. Öncelikle yaşlılarda ve bağışıklık sistemibaskılanmış kişilerde sık görülür. Zoster aşısının kullanılmayabaşlamasının ardından HZ sıklık ve komplikasyonlarında azalmaizlenmekle birlikte HZ, gelişmekte olan ülkeler için halen sorunteşkil etmektedir. Bu çalışmanın amacı HZ tanısıyla takip edilenhastaların demografik özellikleri, hastalıkla ilişkili klinik özelliklerive laboratuvar bulgularını değerlendirmektir.GEREÇ VE YÖNTEM: Mayıs 2014- Mayıs 2018 tarihleri arasındadermatoloji kliniğine HZ tanısıyla başvuran hastalar ICD 10 kodları(B02, B02.3, B02.8, B02.9) taranarak belirlendi. Üç bin sekiz yüzelli altı hastanın elektronik dosya kayıtları geriye dönüşlü olarakincelendi ve hastalık özellikleri kaydedildi.BULGULAR: Hastaların %47,6’sı kadın %52,4’ü erkekti. Ortalamayaş 50,89 (±18.3) olarak hesaplandı. HZ insidansında mevsimleregöre farklılık izlenmedi (ilkbahar: %27,1; yaz: %22,9; sonbahar:%25,6; kış: %24,4). Ancak, hospitalizasyon ve oküler komplikasyonsıklığında sırasıyla ilkbahar (ilkbahar: %36; yaz: %23; sonbahar:%25; kış: %16) ve sonbahar (ilkbahar: %23,1; yaz: %7,7; sonbahar:%53,8; kış: %15,4) aylarında artış görüldü. Oftalmik tutulumhospitalize edilen hastaların %13’ünde izlendi ve yapılan lojistikregresyon analizi yaş, mevsim ve kan platelet dağılım genişliği(PDW) düzeylerinin oküler komplikasyon riski ile ilişkili olduğunugösterdi. Sonbahar mevsiminde başvuran hastalar diğer mevsimlerile karşılaştırıldığında oftalmik tutulum için artmış riske sahiplerdi.Mevsime ek olarak PDW düzeylerindeki her bir birimlik azalma veyaştaki her bir yıllık artış oküler komplikasyon riskini 1,29 (%95GA: 1,01-1,69; p=0,048) ve 1,08 (%95 GA: 1,009-1,156; p=0,026)kat arttırmaktaydı.SONUÇ: HZ epidemiyolojisi ve oftalmik tutulum için riskfaktörlerinin belirlenmesi hasta yönetiminde klinisyene yardımcıolabilir.

🔖

Cite This Article

Yalçın, B., Hayran, Y., Akpınar, Ü. (2022). EVALUATION OF DEMOGRAPHIC, CLINICAL AND LABORATORY CHARACTERISTICS OF PATIENTS FOLLOWED WITH HERPES ZOSTER. Ankara Eğitim ve Araştırma Hastanesi Tıp Dergisi, Cilt: 53 - Sayı: Ek sayı, 33–40. https://ajindex.com/articles/441202

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. )Johnson RW. Herpes zoster and postherpetic neuralgia. Expert Rev Vaccines. 2010
  2. 9(3 Suppl):21-6. 2.)Yawn BP, Gilden D. The global epidemiology of herpes zoster. Neurology. 2013
  3. 81(10):928-30. 3.)Pinchinat S, Cebrian-Cuenca AM, Bricout H, Johnson RW. Similar herpes zoster incidence across Europe: results from a systematic literature review. BMC Infect Dis. 2013
  4. )Tanuseputro P, Zagorski B, Chan KJ, Kwong JC. Population-based incidence of herpes zoster after introduction of a publicly funded varicella vaccination program. Vaccine. 2011
  5. 29(47):8580-4. 5.)Chen N, Li Q, Yang J, Zhou M, Zhou D, He L. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2014(2):CD006866. 6.)Studahl M, Petzold M, Cassel T. Disease burden of herpes zoster in Sweden--predominance in the elderly and in women - a register based study. BMC Infect Dis. 2013
  6. )Johnson RW, Rice AS. Clinical practice. Postherpetic neuralgia. N Engl J Med. 2014
  7. 371(16):1526-33. 8.)Koshy E, Mengting L, Kumar H, Jianbo W. Epidemiology, treatment and prevention of herpes zoster: A comprehensive review. Indian J Dermatol Venereol Leprol. 2018
  8. 84(3):251-62. 9.)Johnson RW, Alvarez-Pasquin MJ, Bijl M, et al. Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective. Ther Adv Vaccines. 2015
  9. 3(4):109-20. 10.)Goh CL, Khoo L. A retrospective study of the clinical presentation and outcome of herpes zoster in a tertiary dermatology outpatient referral clinic. Int J Dermatol. 1997
  10. 36(9):667-72. 11.)Chidiac C, Bruxelle J, Daures JP, et al. Characteristics of patients with herpes zoster on presentation to practitioners in France. Clin Infect Dis. 2001
  11. 33(1):62-9. 12.)Kim YJ, Lee CN, Lim CY, Jeon WS, Park YM. Population-based study of the epidemiology of herpes zoster in Korea. J Korean Med Sci. 2014
  12. 29(12):1706-10. 13.)Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis. 2004
  13. 4(1):26-33. 14.)Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014
  14. 4(6):e004833. 15.)Vukmanovic-Stejic M, Sandhu D, Seidel JA, et al. The Characterization of Varicella Zoster Virus-Specific T Cells in Skin and Blood during Aging. J Invest Dermatol. 2015
  15. 135(7):1752-62. 16.)Garcia-Rojas A, Gil-Prieto R, Nunez-Gallo DA, Matute-Cruz P, Gil-de-Miguel A. Hospitalizations realted to herpes zoster i